Geriatric assessment:: a prospective study in older patients with AML and high-risk MDS

被引：1
|
作者：
Deschler, B. [1 ]
Ihorst, G. [1 ]
Kuhn, M. [1 ]
Rueter, B. [1 ]
Luebbert, M. [1 ]
机构：
[1] Univ Freiburg, Dept Hematol & Oncol, Freiburg, Germany
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2006年 / 60卷
关键词：
D O I：
10.1016/S1040-8428(13)70079-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S26 / S27
页数：2
相关论文
共 50 条
  • [1] A pilot study of bendamustine in elderly patients with high-risk MDS and AML
    Strupp, C.
    Knipp, S.
    Hartmann, J.
    Gattermann, N.
    Haas, R.
    Germing, U.
    [J]. LEUKEMIA & LYMPHOMA, 2007, 48 (06) : 1161 - 1166
  • [2] Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    Ossenkoppele, G. J.
    Breems, D. A.
    Stuessi, G.
    Van Norden, Y.
    Bargetzi, M.
    Biemond, B. J.
    A von dem Borne, P.
    Chalandon, Y.
    Cloos, J.
    Deeren, D.
    Fehr, M.
    Gjertsen, B.
    Graux, C.
    Huls, G.
    Janssen, J. J. J. W.
    Jaspers, A.
    Jongen-Lavrencic, M.
    De Jongh, E.
    Klein, S. K.
    Van der Klift, M.
    Van Marwijk Kooy, M.
    Maertens, J.
    Micheaux, L.
    Van der Poel, M. W. M.
    Van Rhenen, A.
    Tick, L.
    Valk, P.
    Vekemans, M. C.
    Van der Velden, W. J. F. M.
    De Weerdt, O.
    Pabst, T.
    Manz, M.
    Lowenberg, B.
    Havelange
    Vekemans, M-C
    Moors, I.
    Van Obberg, F.
    Maertens, J. A.
    Hodossy, B.
    Vansteenweghen, S.
    Lammertijn, L.
    Sonet, A.
    Triffet, A.
    Gjertsen, B. T.
    Passweg, J.
    Heim, D.
    Giovanni, San
    Stuessi, Georg
    Betticher, D.
    Chalandon, Y.
    [J]. LEUKEMIA, 2020, 34 (07) : 1751 - 1759
  • [3] Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    G. J. Ossenkoppele
    D. A. Breems
    G. Stuessi
    Y. van Norden
    M. Bargetzi
    B. J. Biemond
    P. A von dem Borne
    Y. Chalandon
    J. Cloos
    D. Deeren
    M. Fehr
    B. Gjertsen
    C. Graux
    G. Huls
    J. J. J. W. Janssen
    A. Jaspers
    M. Jongen-Lavrencic
    E. de Jongh
    S. K. Klein
    M. van der Klift
    M. van Marwijk Kooy
    J. Maertens
    L. Michaux
    M. W. M. van der Poel
    A. van Rhenen
    L. Tick
    P. Valk
    M. C. Vekemans
    W. J. F. M. van der Velden
    O. de Weerdt
    T. Pabst
    M. Manz
    B. Löwenberg
    [J]. Leukemia, 2020, 34 : 1751 - 1759
  • [4] A Phase I/II Study Of Cytarabine Or Azacitidine In Combination With Tosedostat In Older Patients With AML Or High-Risk MDS
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Konopleva, Marina
    Kadia, Tapan M.
    Borthakur, Gautam
    Daver, Naval G.
    Durand, Mends
    Rivera, Silvia
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    [J]. BLOOD, 2013, 122 (21)
  • [5] Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
    G. J. Ossenkoppele
    D. A. Breems
    G. Stuessi
    Y. van Norden
    M. Bargetzi
    B. J. Biemond
    P. A von dem Borne
    Y. Chalandon
    J. Cloos
    D. Deeren
    M. Fehr
    B. Gjertsen
    C. Graux
    G. Huls
    J. J. J. W. Janssen
    A. Jaspers
    M. Jongen-Lavrencic
    E. de Jongh
    S. K. Klein
    M. van der Klift
    M. van Marwijk Kooy
    J. Maertens
    L. Michaux
    M. W. M. van der Poel
    A. van Rhenen
    L. Tick
    P. Valk
    M. C. Vekemans
    W. J. F. M. van der Velden
    O. de Weerdt
    T. Pabst
    M. Manz
    B. Löwenberg
    [J]. Leukemia, 2020, 34 : 2820 - 2820
  • [6] Copy number profiles of high-risk MDS and AML patients
    Ganster, C.
    Braulke, F.
    Shirneshan, K.
    Schanz, J.
    Neesen, J.
    Salinas-Riester, G.
    Platzbecker, U.
    Haase, D.
    [J]. ONKOLOGIE, 2013, 36 : 239 - 240
  • [7] Multidimensional geriatric assessment in elderly patients with MDS/AML
    Deschler, B.
    Ihorst, G.
    Perinchery, C.
    Hummel, J.
    Ruter, B.
    Claus, R.
    Lubbert, M.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 64 : S38 - S38
  • [8] An inexpensive way to treat elderly patients with high-risk MDS or AML
    Kuendgen, Andrea
    [J]. LEUKEMIA RESEARCH, 2011, 35 (08) : 985 - 986
  • [9] Randomized study comparing chemotherapy ±GM-CSF in high-risk MDS and AML following MDS (MDS-AML).
    Ohm, AC
    Hast, R
    Bernell, P
    Celsing, F
    Dahl, IM
    Dybedal, I
    Lindberg, G
    Linder, O
    Löfvenberg, E
    Nilsson-Ehle, H
    Samuelsson, J
    Tangen, J
    Turesson, I
    Wallvik, J
    Winquist, I
    Öberg, G
    Björkholm, M
    Hellström-Lindberg, E
    [J]. BLOOD, 2000, 96 (11) : 148A - 148A
  • [10] Determining Treatment for Older Patients with High-Risk MDS and AML: Which Factors Predict Optimal Quality of Life?
    Tinsley-Vance, Sara M.
    Small, Brent J.
    McMillan, Susan C.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    [J]. BLOOD, 2016, 128 (22)
12345